Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | PPARA | Q07869 | 4/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | LAP3 | P28838 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4393180 | 0.93 | LTA4H (0.67) | LTA4HFFAR1FFAR4PPARGPPARA | |
| SCHEMBL5689720 | 0.91 | LTA4H (0.51) | LTA4HFFAR1PPARGPPARAPPARD | |
| SCHEMBL3938329 | 0.88 | ESR1 (0.49) | LTA4HFFAR1PPARGPPARAPPARD | |
| SCHEMBL4755481 | 0.87 | LTA4H (0.54) | LTA4HPPARGPPARAPPARDMAOB | |
| SCHEMBL7492211 | 0.81 | L3MBTL1 (0.64) | LTA4HFFAR1FFAR4PPARGPPARA | |
| SCHEMBL1123147 | 0.81 | GAA (0.71) | LTA4HPPARGMMP9MMP8RAB9A | |
| SCHEMBL3941341 | 0.81 | PPARA (0.60) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL5690301 | 0.81 | PPARG (0.43) | LTA4HFFAR1PPARGPPARAPPARD | |
| SCHEMBL6940318 | 0.81 | PPARA (0.67) | LTA4HFFAR1FFAR4PPARGPPARA | |
| SCHEMBL3204956 | 0.80 | ATM (0.53) | MMP8LAP3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458677-B1 | 3-PHENYL-2-ARYLALKYLTHIOPROPIONIC ACID DERIVATIVES AS SELECTIVE AGONISTS OF PPAR-ALPHA | ASTRAZENECA AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| US-7429675-B2 | Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid | ASTRAZENECA AB (SE) | 2008-09-30 | — | — | US | disclosed |
| US-7276539-B2 | 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha | ASTRAZENECA AB (SE) | 2007-10-02 | — | — | US | disclosed |
| US-20070099928-A1 | Amine salts of (-)-2-{2-(4-hydroxyphenyl) ethyl]thio} -3-4-(2-{4-(methylsulfonyl) oxy phenyl propanoic acid and their use in medicine | ASTRAZENECA (SE) | 2007-05-03 | — | — | US | disclosed |
| US-20060199857-A1 | Therapeutic agents | ASTRAZENECA UK LIMITED (GB) | 2006-09-07 | — | — | US | disclosed |
| US-20060167309-A1 | Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)pheyl]-propanoic acid | ASTRAZENECA AB (SE) | 2006-07-27 | — | — | US | disclosed |
| EP-1641749-A1 | POTASSIUM OR SODIUM SALT OF (-)-2- {'2-(4-HYDROXYPHENYL)ETHYL]-THIO -3-'4-(2- {4-'(METHYLSULFONYL)OXY ]PHENOXY }PHENYL]PROPANOIC ACID AND THEIR USE IN MEDICINE. | Astrazeneca AB (SE) | 2006-04-05 | — | — | EP | disclosed |
| EP-1638930-A1 | AMINE SALTS OF (-)-2- ¬2-(4-HYDROXYPHENYL)ETHYL|-THIO -3-¬4-(2- 4-¬(METHYLSULFONYL)OXY|PHENOXY ETHYL)PHENYL|PROPANOIC ACID AND THEIR USE IN MEDICINE. | Astrazeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1638927-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| US-20050215630-A1 | 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| WO-2004113284-A1 | POTASSIUM OR SODIUM SALT OF (-)-2-{`2-(4-HYDROXYPHENYL)ETHYL!-THIO-3-`4-(2-{4-`(METHZLSULFONZL) OXY !PHENOXY}PHENYL!PROPANOIC ACID AND THEIR USE IN MEDICINE | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113283-A1 | AMINE SALTS OF (-)-2-{`2-(4-HYDROXYPHENYL) ETHYL!-THIO}-3-`4-(2-{4-`(METHYLSULFONYL)OXY! PHENOXY}ETHYL)PHENYL! PROPANOIC ACID AND THERE USE IN MEDICINE | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113282-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099928-A1 | Amine salts of (-)-2-{2-(4-hydroxyphenyl) ethyl]thio} -3-4-(2-{4-(methylsulfonyl) oxy phenyl propanoic acid and their use in medicine | EP300, LIPC, CPT1A | LTA4H 1829/4885FFAR1 212/4885FFAR4 288/4885 |
| US-20050215630-A1 | 3-Phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha | PPARA, PPARG, PPARD | LTA4H 1038/4885FFAR1 5/4885FFAR4 8/4885 |
| US-20060167309-A1 | Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)pheyl]-propanoic acid | HPD, PAH, HAAO | LTA4H 342/4885FFAR1 309/4885FFAR4 124/4885 |
| US-20060199857-A1 | Therapeutic agents | PNLIP, LIPC, GPR119 | LTA4H 1267/4885FFAR1 60/4885FFAR4 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.